Comparison · NCT04527380-deaths
Ixekizumab - OLT Period vs Adalimumab - OLT Period: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ixekizumab - OLT Period vs Adalimumab - OLT Period: deaths from any cause. Trial comparisons, record NCT04527380-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04527380-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0453 | wilson | |
| Risk in group 2 | 0 | 0 | 0.161 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.161 | 0.0453 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ixekizumab - OLT Period | Participants received SC ixekizumab from week 0 to week 16, following dosing regimens based on body weight:~* \> 50.0 kg: Starting dose 160 mg at week 0, then 80 mg SC Q4W from week 2 to week 16.~* 25.0-50.0 kg: Starting dose 80 mg at week 0, then 40 mg SC Q4W from week 2 to week 16.~* 10.0 to \< 25.0 kg: Starting dose 40 mg at week 0, then 20 mg SC Q4W from week 2 to week 16. | 0 | 81 | EG000 |
| Group 2 | Adalimumab - OLT Period | Participants received SC adalimumab from week 0 to week 16, following dosing regimens based on body weight:~* ≥ 30.0 kg: 40 mg SC Q2W.~* 10.0 to \<30.0 kg: 20 mg SC Q2W. | 0 | 20 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Baseline up to week 16 (until OLT period)
Source ClinicalTrials.gov
Trial
- Title
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
- NCT number
- NCT04527380
- Phases
- PHASE3
- Conditions
- Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
- Interventions
- Ixekizumab, Adalimumab
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2025-06-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04527380?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04527380-deaths